Bekanntmachung • Apr 11
Synthomer plc to Report Fiscal Year 2025 Results on Apr 30, 2026 Synthomer plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Apr 30, 2026 Bekanntmachung • Jan 29
Synthomer plc Provides Earnings Guidance for the Twelve Months to 31 December 2025 Synthomer plc provided earnings guidance for the twelve months to 31 December 2025. Company expect to report 2025 revenue of c.£1.74 billion (2024: £1.93bn), in line with market expectations. The continued focus on strong operational execution, together with expanded 'self-help' cost reduction programmes, have enabled to mitigate the impact of softer end-market demand since global tariff changes were announced at the start of Second Quarter and deliver resilient earnings and an increased EBITDA margin. Bekanntmachung • Dec 13
Synthomer PLC Announces Board and Committee Changes Synthomer PLC announced a number of changes to the Board. As previously announced, Ian Tyler and Roberto Gualdoni have now stepped down as independent Non-Executive Directors from the Synthomer Board as planned. Independent Non-Executive Director Janet Ashdown succeeds Ian as Senior Independent Director, and Independent Non-Executive Director Jonathan Silver, who has recent and relevant financial experience for the purposes of the UK Corporate Governance Code, succeeds Ian as Chair of the Audit Committee. Bekanntmachung • Oct 24
Synthomer plc Provides Earnings Guidance for the Year 2026 Synthomer plc provided earnings guidance for the year 2026. As company begin to look to 2026, company anticipate progress in Group earnings and cash generation as a result of full year contributions from self-help actions and product investments. Bekanntmachung • Jun 30
Synthomer plc Announces Board and Committee Changes Synthomer plc announced the appointment of two independent non-executive directors, Janet Ashdown and Jonathan Silver, who will join the Board on 1 July 2025. Janet Ashdown has significant experience of general management primarily in the process and chemicals industries, as well as environmental and sustainability matters, and has chaired corporate remuneration committees for more than 10 years. Janet had a 30-year executive career at BP plc until 2010, running the UK retail and commercial fuel business in her last role there. She then became chief executive of Harvest Energy, until 2013. Janet is currently a non-executive director and remuneration committee chair at Victrex plc, a non-executive director and chair of the remuneration and corporate sustainability committees at RHI Magnesita plc and a non-executive director of Stolt-Nielsen plc. She has previously served as a non-executive director and remuneration committee chair of Marshalls plc and SIG plc, and as senior independent director and chair of committees including for health, safety, security and sustainability of the Nuclear Decommissioning Authority, a UK Government arm's length body. Janet holds a BSc in Energy Engineering from the University of Swansea. Janet will join the Synthomer Board's audit, remuneration and nomination committees on appointment and will succeed Holly Van Deursen as Chair of the Remuneration Committee in late 2026. Jonathan Silver has significant international experience in finance and accounting, risk and controls, treasury, investment management and mergers and acquisitions, having served in a variety of senior roles culminating in chief financial officer during his 30-year executive career to 2015 at Laird plc. Prior to this Jonathan held finance roles at the pharmaceutical and agrichemicals group Fisons plc. Jonathan is currently non-executive director, senior independent director and audit committee chair at Spirent Communications plc. Jonathan also serves as a non-executive director and audit committee chair at Baillie Gifford China Growth Trust plc and at Henderson High Income Trust plc, and previously served in the same roles at Invesco Income Growth Trust plc. He is a Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland. Jonathan holds a BA in Business from the University of Strathclyde. Jonathan will join the Synthomer Board's audit, remuneration and nomination committees on appointment and will succeed Ian Tyler as Chair of the Audit Committee later this year. Further to the announcement of 5 March 2025, Ian Tyler will step down from the Board of Synthomer and his roles as Senior Independent Non-executive Director and Audit Committee Chair in December 2025. Bekanntmachung • Jun 03
H2 Equity Partners Limited and the management of William Blythe Limited completed the acquisition of William Blythe Limited from Synthomer plc (LSE:SYNT). H2 Equity Partners Limited and the management of William Blythe Limited agreed to acquire William Blythe Limited from Synthomer plc (LSE:SYNT) for £30 million on May 6, 2025. A cash consideration of £30 million will be paid by H2 Equity Partners Limited and the management. As part of consideration, £30 million is paid towards common equity of William Blythe Limited. The existing leadership team of Kevin Hudson, Mike Butler and David Crossley will continue to the run William Blythe .
For the period ending December 31, 2024, William Blythe Limited reported total revenue of £54 million and EBITDA of £4 million.
The transaction is conditional on certain customary closing conditions, is expected to complete at the end of May 2025, and the net proceeds will be used to reduce Synthomer net debt. Squire Patton Boggs acted as legal advisors for H2 Equity Partners Limited. Management were supported by Addleshaw Goddard and Park Place.
H2 Equity Partners Limited and the management of William Blythe Limited completed the acquisition of William Blythe Limited from Synthomer plc (LSE:SYNT) on June 2, 2025. The final net cash proceeds of the divestment that were received at completion amount to £25 million after adjustments for working capital, debt and debt-like items, and will be used to reduce the Synthomer plc debt. Chris Carlisle, Daniel Barley of Opus Corporate Finance LLP act as financial advisor for Synthomer plc. Bekanntmachung • May 06
H2 Equity Partners Limited and the management of William Blythe Limited agreed to acquire William Blythe Limited from Synthomer plc (LSE:SYNT) for £30 million. H2 Equity Partners Limited and the management of William Blythe Limited agreed to acquire William Blythe Limited from Synthomer plc (LSE:SYNT) for £30 million on May 6, 2025. A cash consideration of £30 million will be paid by H2 Equity Partners Limited and the management. As part of consideration, £30 million is paid towards common equity of William Blythe Limited.
For the period ending December 31, 2024, William Blythe Limited reported total revenue of £54 million and EBITDA of £4 million.
The transaction is conditional on certain customary closing conditions, is expected to complete at the end of May 2025, and the net proceeds will be used to reduce Synthomer net debt. Bekanntmachung • May 01
Synthomer plc to Report First Half, 2025 Results on Aug 05, 2025 Synthomer plc announced that they will report first half, 2025 results on Aug 05, 2025 Bekanntmachung • Mar 26
Synthomer plc, Annual General Meeting, May 01, 2025 Synthomer plc, Annual General Meeting, May 01, 2025. Location: the offices of the company, 45 pall mall, sw1y 5jg, london United Kingdom Bekanntmachung • Jan 28
Synthomer plc Provides Earnings Guidance for the Year Ended December 31, 2024 Synthomer plc provided earnings guidance for the year ended December 31, 2024. The company expects to report 2024 revenue of c. £2.0 billion (2023: £1,940.6 million) and EBITDA in the range of £145-148 million for the continuing Group (2023: £137.4m), in line with expectations. Continuing Group volume improved further in H2, albeit at a slower rate than in the first half, reflecting mixed end-market demand trends over the period. Within this, volume growth in Fourth Quarter improved relative to Q3, led by the nitrile latex for gloves business in the Health & Protection and Performance Materials (HPPM) division and construction markets within the Coatings & Construction Solutions (CCS) division. The Group also delivered a strong gross margin performance in Q4, reflecting good progress on multi-year cost-saving and reliability improvement programmes, as well as the ongoing strategic re-allocation of capital and other resources towards the higher margin, more resilient speciality solutions within portfolio. Bekanntmachung • Jan 02
Synthomer plc Announces Chair Succession Synthomer plc notes that, as previously announced, Caroline Johnstone stood down as a non-executive and chair of the company, with Peter Hill succeeding her as chair, on 1 January 2025. Bekanntmachung • Oct 31
Synthomer plc to Report Fiscal Year 2024 Results on Mar 11, 2025 Synthomer plc announced that they will report fiscal year 2024 results on Mar 11, 2025 Bekanntmachung • Jul 18
Synthomer plc Announces Board Changes Synthomer plc announced the appointment of Peter Hill CBE as an independent non-executive director and chair designate with effect from 1 September 2024. Following an induction and handover period, Caroline Johnstone will stand down from the board, with Peter succeeding her as chair, on 1 January 2025. Peter brings to Synthomer strong public company governance and international manufacturing experience in a range of industries. Peter has served as non-executive chair of Keller Group plc since 2016, a role from which he will step down during the first half of 2025, having served approximately nine years. Previously Peter was non-executive chair of Petra Diamonds Limited (2020-2023), Volution Group plc (2014-2020), Imagination Technologies plc (February 2017 until its sale in September 2017) and the speciality chemicals company Alent plc (2012-2015). He is currently non-executive chair of The Nuclear Decommissioning Authority, a UK Government arm's length body sponsored by the Department for Energy Security and Net Zero. Peter has also served as a non-executive director on the boards of Cookson Group plc, Meggitt plc, Essentra plc and Oxford Instruments plc, and in similar roles for UK Trade and Investment and the Royal Air Force. He was chief executive officer of Laird plc from 2002 to late 2011, transforming it from an industrial conglomerate into a focused electronics and technology company. He previously held senior management roles at BTR plc and Invensys plc, and was an executive director on the board of Costain Group plc. Peter's early career was spent with natural resources companies Anglo American, Rio Tinto and BP Minerals. He holds a BSc in engineering, an MBA from the London The Honourable Alexander Catto has advised the board of his intention to step down as a director by the Group's next Annual General Meeting (AGM) in May 2025. As a non-independent, non-executive director of the Group, he has served as representative of its founding family and significant shareholders since 1981. More recently, he has served as the designated non-executive director leading workforce engagement. The Group announced the appointment of Uwe Halder to the board with effect from 1 September 2024. Uwe is chief executive officer of KLK OLEO Europe, part of the global oleochemical and manufacturing division of Kuala Lumpur Kepong Berhad (KLK), which is Synthomer's large shareholder (with 27% of the issued share capital). Uwe's entire career has been in the global chemicals industry. He has worked in the USA at BASF and as president of DyStar USA, and in Europe at CHT/BEZEMA and Archroma before joining a business acquired by KLK OLEO. As a nominee of KLK, Uwe will be a non-independent, non-executive director upon appointment. The changes announced reflect the board's long-term succession planning agenda which will continue to evolve to reflect the Group's strategy, skills and experience needs and compliance with Corporate Governance Code principles. Bekanntmachung • May 10
Synthomer plc to Report First Half, 2024 Results on Aug 13, 2024 Synthomer plc announced that they will report first half, 2024 results on Aug 13, 2024 Recent Insider Transactions • Mar 31
CEO & Executive Director recently bought UK£112k worth of stock On the 27th of March, Michael Willome bought around 47k shares on-market at roughly UK£2.38 per share. This transaction amounted to 75% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of UK£218k worth in shares. Reported Earnings • Mar 14
Full year 2023 earnings released: UK£1.20 loss per share (vs UK£1.09 loss in FY 2022) Full year 2023 results: UK£1.20 loss per share (further deteriorated from UK£1.09 loss in FY 2022). Revenue: UK£1.97b (down 17% from FY 2022). Net loss: UK£102.5m (loss widened 304% from FY 2022). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 3.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 6 percentage points per year, which is a significant difference in performance. New Risk • Mar 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Buy Or Sell Opportunity • Feb 12
Now 29% overvalued Over the last 90 days, the stock has fallen 29% to UK£1.49. The fair value is estimated to be UK£1.15, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 1.5% in 2 years. Earnings are forecast to grow by 97% in the next 2 years. Bekanntmachung • Jan 30
Synthomer plc Provides Earnings Guidance for the Year 2023 Synthomer plc provided earnings guidance for the year 2023. For the year, The company expects to report revenue of £2.0 billion in 2023. New Risk • Jan 21
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: UK£170k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Significant insider selling over the past 3 months (UK£170k sold). Buying Opportunity • Jan 11
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 26%. The fair value is estimated to be UK£2.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 0.3% in a year. Earnings is forecast to grow by 85% in the next year. Bekanntmachung • Dec 07
Synthomer plc, Annual General Meeting, May 09, 2024 Synthomer plc, Annual General Meeting, May 09, 2024. Bekanntmachung • Nov 15
Synthomer plc to Report Fiscal Year 2023 Results on Mar 12, 2024 Synthomer plc announced that they will report fiscal year 2023 results on Mar 12, 2024 Recent Insider Transactions • Nov 06
Non-Executive Director recently bought UK£170k worth of stock On the 30th of October, Alexander Catto bought around 91k shares on-market at roughly UK£1.87 per share. This transaction increased Alexander's direct individual holding by 3x at the time of the trade. In the last 3 months, they made an even bigger purchase worth UK£774k. Insiders have collectively bought UK£1.4m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Oct 19
Non-Executive Director recently bought UK£774k worth of stock On the 13th of October, Alexander Catto bought around 393k shares on-market at roughly UK£1.97 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£1.4m more in shares than they have sold in the last 12 months. New Risk • Oct 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Bekanntmachung • Oct 14
Synthomer plc has completed a Follow-on Equity Offering in the amount of £276.195611 million. Synthomer plc has completed a Follow-on Equity Offering in the amount of £276.195611 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 140,200,818
Price\Range: £1.97
Discount Per Security: £0.0522
Transaction Features: Regulation S; Rights Offering; Rule 144A Reported Earnings • Sep 08
First half 2023 earnings released: UK£0.11 loss per share (vs UK£0.18 profit in 1H 2022) First half 2023 results: UK£0.11 loss per share (down from UK£0.18 profit in 1H 2022). Revenue: UK£1.08b (down 19% from 1H 2022). Net loss: UK£50.9m (down 160% from profit in 1H 2022). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 46% per year whereas the company’s share price has fallen by 47% per year. Board Change • Sep 05
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Senior Independent Director Ian Tyler was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. New Risk • Jul 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change). Bekanntmachung • Jul 13
Synthomer plc Appoints Martina Flöel as Non-Executive Director Synthomer plc has appointed Martina Flöel as a Non-Executive Director. She will join the Board and become a member of the Audit, Remuneration, and Nomination Committees with effect from 1 September 2023. Martina has considerable executive experience in the chemical industry. Between 2003 and 2016, she led what became OXEA GmbH, after its creation as a joint venture between Celanese AG and Degussa AG, during which time the business grew considerably through a focus on specialisation. Prior to this, Martina held a number of senior roles at Celanese and its predecessor company, Hoechst AG, focusing on strategy, operations and capital investment, human resources, and innovation and technology. Martina began her career as a research chemist at Hoechst after receiving a PhD in chemistry from the Technical University of Munich. Martina has extensive Non-Executive Board experience, having served since 2018 on the Board of Sasol Limited, the global chemicals and energy company (US and South Africa-listed), including as a member of the Remuneration, Capital Investment, Digital and Safety, Sustainability, and Ethics Committees. Between 2017 and March 2023, Martina was a supervisory Board member of Finnish-listed Neste Corporation, the renewable and circular solutions-focused refinery company, serving as a member of the Audit and Remuneration Committees. Between 2019 and 2020, Martina also served on the supervisory Board of a family-owned company in Germany. Buying Opportunity • Jun 22
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 44%. The fair value is estimated to be UK£0.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 4.2% in a year. Earnings is forecast to decline by 20% in the next year. Bekanntmachung • May 16
Synthomer plc Announces Retirement of Brendan Connolly from the Board Synthomer plc announced that Brendan Connolly will retire from the Board at the end of today's AGM, as previously announced, having served a nine-year term as a Non-Executive Director of the Group. He is succeeded by Ian Tyler as Senior Independent Director, and by Holly Van Deursen as Chair of the Remuneration Committee, with immediate effect. Reported Earnings • Mar 29
Full year 2022 earnings released: UK£0.054 loss per share (vs UK£0.48 profit in FY 2021) Full year 2022 results: UK£0.054 loss per share (down from UK£0.48 profit in FY 2021). Revenue: UK£2.38b (up 2.3% from FY 2021). Net loss: UK£25.4m (down 112% from profit in FY 2021). Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Bekanntmachung • Jan 31
Synthomer plc to Report Fiscal Year 2022 Results on Mar 28, 2023 Synthomer plc announced that they will report fiscal year 2022 results on Mar 28, 2023 Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment improved over the past week After last week's 16% share price gain to UK£1.36, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 57% over the past three years. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CFO & Director Lily Liu was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Oct 26
Investor sentiment improved over the past week After last week's 26% share price gain to UK£1.16, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 16x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 54% over the past three years. Upcoming Dividend • Sep 29
Upcoming dividend of UK£0.04 per share Eligible shareholders must have bought the stock before 06 October 2022. Payment date: 04 November 2022. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 18%. Within top quartile of British dividend payers (6.1%). Higher than average of industry peers (3.1%). Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 17% share price decline to UK£1.38, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£2.62 per share. Reported Earnings • Aug 03
First half 2022 earnings released: EPS: UK£0.18 (vs UK£0.47 in 1H 2021) First half 2022 results: EPS: UK£0.18 (down from UK£0.47 in 1H 2021). Revenue: UK£1.33b (up 8.5% from 1H 2021). Net income: UK£85.4m (down 57% from 1H 2021). Profit margin: 6.4% (down from 16% in 1H 2021). Over the next year, revenue is forecast to grow 9.1% compared to a 20% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Board Change • Aug 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CFO & Director Lily Liu was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 25
Upcoming dividend of UK£0.21 per share Eligible shareholders must have bought the stock before 01 June 2022. Payment date: 05 July 2022. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 9.7%. Within top quartile of British dividend payers (4.8%). Higher than average of industry peers (2.7%). Recent Insider Transactions • Mar 11
Non-Executive Director recently bought UK£615k worth of stock On the 9th of March, Hau-Hian Lee bought around 224k shares on-market at roughly UK£2.75 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£1.3m more in shares than they have sold in the last 12 months. Reported Earnings • Mar 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: UK£0.48 (up from UK£0.007 in FY 2020). Revenue: UK£2.33b (up 42% from FY 2020). Net income: UK£208.7m (up UK£205.6m from FY 2020). Profit margin: 9.0% (up from 0.2% in FY 2020). Revenue exceeded analyst estimates by 1.6%. Over the next year, revenue is forecast to grow 6.3% compared to a 10% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Dec 24
Non-Executive Director recently bought UK£135k worth of stock On the 20th of December, Alexander Catto bought around 35k shares on-market at roughly UK£3.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£582k more in shares than they have sold in the last 12 months. Executive Departure • Oct 06
Independent Non-Executive Director Just J. Jansz has left the company On the 29th of September, Just J. Jansz's tenure as Independent Non-Executive Director ended after 9.5 years in the role. As of June 2021, Just J. still personally held 12.50k shares (UK£62k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.75 years. Upcoming Dividend • Sep 30
Upcoming dividend of UK£0.087 per share Eligible shareholders must have bought the stock before 07 October 2021. Payment date: 04 November 2021. Trailing yield: 3.5%. Lower than top quartile of British dividend payers (4.0%). Higher than average of industry peers (1.7%). Executive Departure • Sep 03
Independent Non-Executive Director Just J. Jansz has left the company On the 31st of August, Just J. Jansz's tenure as Independent Non-Executive Director ended after 9.4 years in the role. As of June 2021, Just J. still personally held 12.50k shares (UK£62k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.67 years. Reported Earnings • Aug 06
First half 2021 earnings released: EPS UK£0.47 (vs UK£0.031 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£1.23b (up 68% from 1H 2020). Net income: UK£200.3m (up UK£213.4m from 1H 2020). Profit margin: 16% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Upcoming Dividend • May 27
Upcoming dividend of UK£0.086 per share Eligible shareholders must have bought the stock before 03 June 2021. Payment date: 05 July 2021. Trailing yield: 2.2%. Lower than top quartile of British dividend payers (4.1%). Higher than average of industry peers (1.5%). Recent Insider Transactions • Apr 04
Key Executive recently bought UK£148k worth of stock On the 26th of March, Calum MacLean bought around 32k shares on-market at roughly UK£4.63 per share. In the last 3 months, there was an even bigger purchase from another insider worth UK£225k. This was Calum's only on-market trade for the last 12 months. Reported Earnings • Apr 02
Full year 2020 earnings released: EPS UK£0.007 (vs UK£0.21 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: UK£1.64b (up 13% from FY 2019). Net income: UK£3.10m (down 96% from FY 2019). Profit margin: 0.2% (down from 5.8% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Mar 21
Non-Executive Director recently bought UK£225k worth of stock On the 19th of March, Hau-Hian Lee bought around 49k shares on-market at roughly UK£4.65 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£324k more in shares than they have sold in the last 12 months. Reported Earnings • Mar 05
Full year 2020 earnings released: EPS UK£0.007 (vs UK£0.21 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: UK£1.64b (up 13% from FY 2019). Net income: UK£3.10m (down 96% from FY 2019). Profit margin: 0.2% (down from 5.8% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Analyst Estimate Surprise Post Earnings • Mar 05
Revenue misses expectations Revenue missed analyst estimates by 3.6%. Over the next year, revenue is forecast to grow 21% compared to a 8.0% decline forecast for the Chemicals industry in the United Kingdom. Is New 90 Day High Low • Feb 12
New 90-day high: UK£4.62 The company is up 10.0% from its price of UK£4.21 on 13 November 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£6.28 per share. Is New 90 Day High Low • Dec 30
New 90-day high: UK£4.52 The company is up 44% from its price of UK£3.13 on 01 October 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£4.90 per share. Is New 90 Day High Low • Dec 05
New 90-day high: UK£4.50 The company is up 46% from its price of UK£3.09 on 04 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£4.19 per share. 
